UniSuper Management Pty Ltd Grows Stock Position in Stryker Co. (NYSE:SYK)

UniSuper Management Pty Ltd lifted its stake in Stryker Co. (NYSE:SYK) by 31.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,501 shares of the medical technology company’s stock after buying an additional 5,117 shares during the quarter. UniSuper Management Pty Ltd’s holdings in Stryker were worth $7,741,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SYK. Sava Infond d.o.o. purchased a new stake in Stryker in the 4th quarter worth approximately $1,494,000. WINTON GROUP Ltd purchased a new stake in Stryker during the fourth quarter worth $4,372,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Stryker by 9.8% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 547,780 shares of the medical technology company’s stock valued at $198,032,000 after buying an additional 48,788 shares during the period. Cottage Street Advisors LLC increased its holdings in Stryker by 0.9% in the fourth quarter. Cottage Street Advisors LLC now owns 11,188 shares of the medical technology company’s stock valued at $4,028,000 after buying an additional 100 shares in the last quarter. Finally, Graney & King LLC acquired a new position in shares of Stryker in the fourth quarter worth about $117,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of SYK stock opened at $367.87 on Friday. The firm’s 50-day moving average is $384.47 and its two-hundred day moving average is $374.24. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The company has a market capitalization of $140.37 billion, a PE ratio of 47.41, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the business earned $3.46 earnings per share. Analysts predict that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is presently 43.30%.

Analyst Ratings Changes

SYK has been the subject of several recent analyst reports. Wells Fargo & Company lifted their price target on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Stifel Nicolaus boosted their price objective on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. The Goldman Sachs Group set a $422.00 target price on Stryker in a research report on Tuesday, March 4th. Needham & Company LLC reissued a “buy” rating and issued a $442.00 price target on shares of Stryker in a report on Friday, March 21st. Finally, Citigroup reaffirmed a “buy” rating and set a $450.00 price objective on shares of Stryker in a report on Wednesday, February 26th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $421.90.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.